
Shares of drugmaker Emergent BioSolutions EBS.N fall 3% to $5.60, hit nine-month low
India's Syngene International SYNN.NS says it has acquired its first biologics facility in the U.S. from Emergent Manufacturing Operations Baltimore, a unit of EBS, for $36.5 million
The deal is expected to close in March, 2025
Co says the facility is expected to be operational for client projects from the H2 2025
Up to last close, EBS has risen more than double in the past 12 months